GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (XTER:YP1A) » Definitions » Pretax Margin %

Immutep (XTER:YP1A) Pretax Margin % : % (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Immutep Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Immutep's Pre-Tax Income for the three months ended in Dec. 2023 was €0.00 Mil. Immutep's Revenue for the three months ended in Dec. 2023 was €0.00 Mil. Therefore, Immutep's pretax margin for the quarter that ended in Dec. 2023 was %.

The historical rank and industry rank for Immutep's Pretax Margin % or its related term are showing as below:


XTER:YP1A's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -167.31
* Ranked among companies with meaningful Pretax Margin % only.

Immutep Pretax Margin % Historical Data

The historical data trend for Immutep's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immutep Pretax Margin % Chart

Immutep Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13,109.30 -179.90 - -18,950.44 -

Immutep Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Immutep's Pretax Margin %

For the Biotechnology subindustry, Immutep's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immutep's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immutep's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Immutep's Pretax Margin % falls into.



Immutep Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Immutep's Pretax Margin for the fiscal year that ended in Jun. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Jun. 2023 )/Revenue (A: Jun. 2023 )
=-24.714/0
= %

Immutep's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=0/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immutep  (XTER:YP1A) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Immutep Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Immutep's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Immutep (XTER:YP1A) Business Description

Traded in Other Exchanges
Address
264 George Street, Level 33, Australia Square, Sydney, NSW, AUS, 2000
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.

Immutep (XTER:YP1A) Headlines

No Headlines